Seoul St. Mary's Hospital Develops AI-Powered Patient Screening Technology for Cancer Clinical Trials
Recently, research on new drug development using artificial intelligence (AI) technology has been actively underway in the domestic medical community. Amidst this trend, Seoul St. Mary's Hospital announced that it has developed AI software that automatically screens multiple myeloma patients to determine their eligibility for clinical trials.
Multiple myeloma is a type of blood cancer, and because symptoms and conditions vary from patient to patient, finding suitable candidates for clinical trials has required a significant amount of time and effort. Previously, it was pointed out that efficiency was low because medical staff had to manually review each patient's data.
The newly developed AI software quickly analyzes a patient's complex medical records to automatically identify those who meet clinical trial criteria. This is expected to reduce the workload of medical staff and enable patients to participate in clinical trials for new drugs tailored to them more quickly and accurately.
Experts anticipate that this technological development will be a great help in accelerating the speed of new drug development. It is particularly significant in that it can provide new treatment opportunities to more patients by increasing the efficiency of clinical trials.
Attention is now focused on how this AI software will be utilized in actual clinical settings. The industry is watching to see how much further this technological advancement will transform the domestic new drug development environment into a smarter one.